MabSpace Biosciences

MabSpace Biosciences, is a biotech company focused on discovery and development of innovative antibody based therapeutics for cancer and fibrotic diseases. It was founded in 2013 by indrustrial veterans and is located in Biobay Suzhou, an emerging bitech incubator in China. MabSpace employes its proprietary platform technology, immune tolerance breaking technology (IMBT), to generate lead antibodies with diverse epitopes. MabSpace has established multiple antibody discovery and co-development partnerships based on this technology. MabSpace raised 15 million USD from Lilly Asia Ventures in 2015 to advance its lead antibody program, a potentially best-in-class anti-PD-L1 antibody with unique pH-dependent binding and recycling property and significantly improved efficacy in animal models. It has also built a panel of 2nd generation immuno-oncology antibodies targeting different components of the tumor microenvironment,which enables the testing of combination therapeutic interventions with its PD-L1 antibody.

MabSpace Biosciences headquartered in Asia, operates in the Biotechnology, Medical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $1.3B in funding across 24 round(s). With a team of 11-50 employees, MabSpace Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - MabSpace Biosciences, raised $15.0M. Discover more about their projects, partnerships, and impact on our platform.